As an entrepreneur, venture capitalist and former practicing physician, Steve knows firsthand the challenges of building successful healthcare companies. Unfazed by complexity in healthcare, whether scientific, regulatory, or market driven, Steve’s mission has been to make healthcare delivery more effective and affordable.
Before co-founding EvolveImmune, Steve helped start and finance leading healthcare companies as a general partner at Canaan Partners. Steve has served on the boards of companies in biopharma, digital health, medical devices and diagnostics, often as board chairman. Steve is currently chairman of the board at Liquidia (LQDA-NASDAQ), executive chairman of Allyx Therapeutics and is a member of Dartmouth Medical School’s Board of Advisors.
Before joining Canaan in 2002, Steve helped found and manage multiple start-ups, including RMS, one of the first radiology benefits companies where he was CEO for 6 years. Previously, Steve was a strategic pharmaceutical consultant for Arthur D. Little and a Ewing Marion Kauffman Fellow.
Steve obtained his AB from Dartmouth College, a MA in the history of science from Harvard, and his medical degree from the University of Rochester. Steve completed his residency at Massachusetts General Hospital/Harvard Medical School (radiology) and Lenox Hill Hospital/Cornell Medical School (internal medicine).